Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Rosario Pivonello; Irina Bancos; Richard A Feelders; Atil Y Kargi; Janice M Kerr; Murray B Gordon; Cary N Mariash; Massimo Terzolo; Noel Ellison; Andreas G Moraitis

doi:10.3389/fendo.2022.899616

Back

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Journal article

Open access

Peer reviewed

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Rosario Pivonello, Irina Bancos, Richard A Feelders, Atil Y Kargi, Janice M Kerr, Murray B Gordon, Cary N Mariash, Massimo Terzolo, Noel Ellison and Andreas G Moraitis

Frontiers in endocrinology (Lausanne), Vol.13, pp.899616-899616

2022

DOI: https://doi.org/10.3389/fendo.2022.899616

PMID: 35574017

Appears in Miller School of Medicine - Latest Publications

Abstract

clinical trial

hypercortisolism

cortisol

hyperglycemia

glucocorticoid

Cushing syndrome

relacorilant

hypertension

[This corrects the article DOI: 10.3389/fendo.2021.662865.].

Files and links (1)

url

https://doi.org/10.3389/fendo.2022.899616View

Published (Version of record) Open

Metrics

9 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.164 Endocrinology & Metabolism; 1.164.646 Acromegaly
Web Of Science research areas: Endocrinology & Metabolism
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Creators: Rosario Pivonello - University of Naples Federico II
Irina Bancos - Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, United States
Richard A Feelders - Erasmus MC
Atil Y Kargi - University of Miami
Janice M Kerr - University of Colorado Denver
Murray B Gordon - Allegheny General Hospital
Cary N Mariash - Indiana University
Massimo Terzolo - University of Turin
Noel Ellison - Trialwise, Inc, Houston, TX, United States
Andreas G Moraitis - Corcept Therapeutics
Publication Details: Frontiers in endocrinology (Lausanne), Vol.13, pp.899616-899616
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Endocrinology, Diabetes & Metabolism
Language: English
Resource Type: Journal article
PMID: 35574017
Record Identifier: 991031713256102976